Seminars in oncology
-
Seminars in oncology · Aug 1992
ReviewRationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations.
The identification of several safe and effective agents for the control of chemotherapy-induced nausea and vomiting has prompted an intensive effort to develop combination antiemetic regimens. The principal rationale for development of drug combinations is the potential for blocking different types of neurotransmittor receptors controlling the emetic process. ⋯ Preliminary data show that ondansetron can be combined with dexamethasone safely with enhanced antiemetic results. Ondansetron merits further study in combination antiemetic programs.
-
Seminars in oncology · Jun 1992
ReviewToward bloodless surgery: erythropoietin therapy in the surgical setting.
Issues related to blood safety and blood inventory have recently led to a much greater interest in blood conservation measures. Some of these measures have included using lower transfusion triggers (hematocrit values), directed donor programs, and autologous blood transfusions. When possible, autologous blood donation is the preferable alternative because it represents the safest blood, conserves blood inventories, and has a salutary effect on physician transfusion behavior. ⋯ Continuing medical education can be effectively used to alter physician behavior regarding underordering. Early clinical trials have suggested that recombinant human erythropoietin (r-HuEPO) can be effectively used to increase the volume of autologous blood obtained before surgery and to prevent the anemia caused by serial phlebotomy. Determining the optimal dose, route, and interval of administration of r-HuEPO is currently the object of ongoing investigations.